Systemic treatment of endometrial cancer: What is doxorubicin's role?

Journal of Clinical Oncology

Volumn 32, Issue 20, 2014, Pages 2181-2182

  Goldfinger, Mendel ^a   Diaz, Isabela ^b   Muggia, Franco ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HOSPITAL DE GALDAKAO   (Spain)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ENDOMETRIUM CARCINOMA; HUMAN; LETTER; OVARY CANCER; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 84905865816     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.7454     Document Type: Letter

References (19)

1. Randall ME, Filiaci VL, Muss H, et al: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 24:36-44, 2006 (Pubitemid 46630491)
2. Thigpen JT, Buchsbaum HJ, Mangan C, et al: Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 63:21-27, 1979 (Pubitemid 9152662)
3. Ball HG, Blessing JA, Lentz SS, et al: A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 62:278-281, 1996 (Pubitemid 26274811)
4. Fleming GF, Brunetto VL, Cella D, et al: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 22:2159-2166, 2004 (Pubitemid 41095150)
5. Miller D, Fillaci V, Fleming G, et al: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 125:771-773, 2012
6. Thigpen JT, Blessing JA, DiSaia PJ, et al: A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 12:1408-1414, 1994 (Pubitemid 24206239)
7. Thigpen JT, Brady MF, Homesley HD, et al: Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 22:3902-3908, 2004 (Pubitemid 41079871)
8. Gallion HH, Brunetto VL, Cibull M, et al: Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 21:3808-3813, 2003 (Pubitemid 46606236)
9. Fleming GF, Filiaci VL, Bentley RC, et al: Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: A Gynecologic Oncology Group study. Ann Oncol 15:1173-1178, 2004 (Pubitemid 39199303)
10. DiSaia PJ (ed): Gynecologic Oncology Group: 43 Years of Success. Philadelphia, PA, GOG Publications, 2013
11. [No authors listed]: FIGO News: News from the secretariat. Int J Gynecol Obstet 28:189-193, 198
12. Muggia FM, Blessing JA, Sorosky J, et al: Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 20:2360-2364, 2002 (Pubitemid 34441664)
13. Homesley HD, Blessing JA, Sorosky J, et al: Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 98:294-298, 2005 (Pubitemid 41019119)
14. Escobar PF, Markman M, Zanotti K, et al: Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol 129:651-654, 2003 (Pubitemid 37452631)
15. Balbi G, Visconti S, Monteverde A, et al: Liposomal doxorubicin: A phase II trial. Acta Biomed 78:210-213, 2007 (Pubitemid 351599001)
16. Pignata S, Scambia G, Pisano C, et al: A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: The END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer 96:1639-1643, 2007 (Pubitemid 46847208)
17. du Bois A, Pfisterer J, Burchardi N, et al: Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 107:518-525, 2007 (Pubitemid 350160867)
18. Lê LH, Swenerton KD, Elit L, et al: Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies. Int J Gynecol Cancer 15:799-806, 2005 (Pubitemid 41783084)
19. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al: Integrated genomic characterization of endometrial carcinoma. Nature 497:67-73, 2013